(NASDAQ: ATRA) Atara Biotherapeutics's forecast annual earnings growth rate of -39.7% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.49%.
Atara Biotherapeutics's earnings in 2026 is $23,401,000.On average, 6 Wall Street analysts forecast ATRA's earnings for 2026 to be $551,583, with the lowest ATRA earnings forecast at -$5,087,542, and the highest ATRA earnings forecast at $6,586,550. On average, 5 Wall Street analysts forecast ATRA's earnings for 2027 to be -$13,679,258, with the lowest ATRA earnings forecast at -$21,127,431, and the highest ATRA earnings forecast at -$5,526,645.
In 2028, ATRA is forecast to generate $13,863,119 in earnings, with the lowest earnings forecast at $7,207,351 and the highest earnings forecast at $20,819,554.